Cargando…

Novel Lawsone–Quinoxaline Hybrids as New Dual Binding Site Acetylcholinesterase Inhibitors

[Image: see text] A new family of lawsone–quinoxaline hybrids was designed, synthesized, and evaluated as dual binding site cholinesterase inhibitors (ChEIs). In vitro tests revealed that compound 6d was the most potent AChEI (IC(50) = 20 nM) and BChEI (IC(50) = 220 nM). The compound 6d did not show...

Descripción completa

Detalles Bibliográficos
Autores principales: Suwanhom, Paptawan, Nualnoi, Teerapat, Khongkow, Pasarat, Tipmanee, Varomyalin, Lomlim, Luelak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500570/
https://www.ncbi.nlm.nih.gov/pubmed/37720764
http://dx.doi.org/10.1021/acsomega.3c02683
Descripción
Sumario:[Image: see text] A new family of lawsone–quinoxaline hybrids was designed, synthesized, and evaluated as dual binding site cholinesterase inhibitors (ChEIs). In vitro tests revealed that compound 6d was the most potent AChEI (IC(50) = 20 nM) and BChEI (IC(50) = 220 nM). The compound 6d did not show cytotoxicity against the SH-SY5Y neuronal cells (GI(50) > 100 μM). In silico and enzyme kinetic experiments demonstrated that compound 6d bound to both the catalytic anionic site and the peripheral anionic site of HuAChE. The lawsone–quinoxaline hybrids exhibited potential for further development of potent acetylcholinesterase inhibitors for the treatment of Alzheimer’s disease.